Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

Journal of Medicinal Chemistry

Volumn 56, Issue 4, 2013, Pages 1573-1582

  Liu, Shu ^a   Premnath, Padmavathy Nandha ^a   Bolger, Joshua K ^a   Perkins, Tracy L ^a   Kirkland, Lindsay O ^a   Kontopidis, George ^b   McInnes, Campbell ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,5 DICHLOROPHENYL) 5 METHYL 1H 1,2,4 TRIAZOLE 3 CARBOXYLIC ACID; 1 (3,5 DICHLOROPHENYL) 5 METHYL 1H PYRAZOLE 3 CARBOXYLIC ACID; 1 (4 CHLOROPHENYL) 1H PYRROLE 3 CARBALDEHYDE; 1 (4 CHLOROPHENYL) 1H PYRROLE 3 CARBOXYLIC ACID; 2 (3 FLUOROPHENYL) 1H IMIDAZOLE 4 CARBOXYLIC ACID; 5 (3,5 DICHLOROPHENYL)FURAN 2 CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; ETHYL 1 (3,5 DICHLOROPHENYL) 5 METHYL 1H 1,2,4 TRIAZOLE 3 CARBOXYLATE; ETHYL 1 (3,5 DICHLOROPHENYL) 5 METHYL 1H PYRAZOLE 3 CARBOXYLATE; ETHYL 2 (3 FLUOROPHENYL) 1H IMIDAZOLE 4 CARBOXYLATE; UNCLASSIFIED DRUG; [4 (3 CHLOROPHENOXY)PYRIDIN 2 YL]METHANAMINE;

ARTICLE; COVALENT BOND; CRYSTAL STRUCTURE; HYDROGEN BOND; PROCESS OPTIMIZATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 84874607678     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013882     Document Type: Article

References (24)

1. Sherr, C. J. Cancer cell cycles Science 1996, 274, 1672-1677
2. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer Nat. Rev. Cancer 2001, 1, 222-231 (Pubitemid 33741897)
3. McInnes, C.; Andrews, M. J. I.; Zheleva, D. I.; Lane, D. P.; Fischer, P. M. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 57-69 (Pubitemid 36131635)
4. Oelgeschlager, T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control J. Cell. Physiol. 2002, 190, 160-169 (Pubitemid 34027819)
5. WAF1 derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A J. Pept. Res. 2002, 60, 257-270 (Pubitemid 35246787)
6. Chen, Y. N.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; Baker, K.; Adams, P. D.; Bair, K. W.; Kaelin, W. G., Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4325-4329 (Pubitemid 29190335)
7. Schulman, B. A.; Lindstrom, D. L.; Harlow, E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10453-10458 (Pubitemid 28413088)
8. Ball, K. L.; Lain, S.; FaÌŠhraeus, R.; Smythe, C.; Lane, D. P. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 Curr. Biol. 1996, 7, 71-80 (Pubitemid 27058942)
9. Mendoza, N.; Fong, S.; Marsters, J.; Koeppen, H.; Schwall, R.; Wickramasinghe, D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth Cancer Res. 2003, 63, 1020-1024 (Pubitemid 36278433)
10. Andrews, M. J.; Kontopidis, G.; McInnes, C.; Plater, A.; Innes, L.; Cowan, A.; Jewsbury, P.; Fischer, P. M. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors ChemBioChem 2006, 7, 1909-1915 (Pubitemid 44893525)
11. Kontopidis, G.; Andrews, M. J.; McInnes, C.; Cowan, A.; Powers, H.; Innes, L.; Plater, A.; Griffiths, G.; Paterson, D.; Zheleva, D. I.; Lane, D. P.; Green, S.; Walkinshaw, M. D.; Fischer, P. M. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange Structure 2003, 11, 1537-1546 (Pubitemid 37510353)
12. Castanedo, G.; Clark, K.; Wang, S.; Tsui, V.; Wong, M.; Nicholas, J.; Wickramasinghe, D.; Marsters, J. C., Jr.; Sutherlin, D. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads Bioorg. Med. Chem. Lett. 2006, 16, 1716-1720 (Pubitemid 43197552)
13. McInnes, C.; Estes, K.; Yang, Z.; Farag, D. B.; Johnson, P.; Lazo, J.; Michael, D. W. Targeting sub-cellular localization through the Polo-Box domain: non-ATP competitive inhibitors recapitulate a PLK1phenotype Mol. Cancer Ther. 2012, 8, 1683-1692
14. Pfefferkorn, J. A.; Choi, C.; Larsen, S. D.; Auerbach, B.; Hutchings, R.; Park, W.; Askew, V.; Dillon, L.; Hanselman, J. C.; Lin, Z.; Lu, G. H.; Robertson, A.; Sekerke, C.; Harris, M. S.; Pavlovsky, A.; Bainbridge, G.; Caspers, N.; Kowala, M.; Tait, B. D. Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: Discovery of (3 R,5 R)-7-[2-(4-fluorophenyl)-4- isopropyl-5-(4-methylbenzylcarbamoyl)-2 H -pyrazo l-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia J. Med. Chem. 2008, 51, 31-45
15. Wang, L.-Y.; Tseng, W.-C.; Lin, H-Y.; Wong, F. F. An effective nitrilimine cycloaddition for the synthesis of 1,3,5-trisubstituted 1,2,4-triazoles from oximes with hydrazonoyl hydrochlorides Synlett 2011, 10, 1467-1471
16. Atkinson, R. N.; Drizin, I.; Gregg, R. J.; Gross, M. F.; Kort, M. E.; Shi, L. Pyrazole-amides and sulfonamides as sodium channel modulators. U.S. Patent 2005/0020564, 2005.
17. Prasad, D. J.; Karthikeyan, M. S.; Karegoudar, P. B.; Poojary, B.; Holla, B. S.; Kumari, N. S. Synthesis of some thiadiazolotriazinone derivatives as possible antimicrobial agents Phosphorus, Sulfur, Silicon Relat. Elem. 2007, 182, 1083-1091
18. Sbardella, G.; Mai, A.; Artico, M.; Loddo, R.; Setzu, M. G.; La Colla, P. Synthesis and in vitro antimycobacterial activity of novel 3-(1 H -pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480 Bioorg. Med. Chem. Lett. 2004, 14, 1537-1541 (Pubitemid 38299445)
19. Paul, R.; Brockman, J. A.; Hallett, W. A.; Hanifin, J. W.; Tarrant, M. E.; Torley, L. W.; Callahan, F. M.; Fabio, P. F.; Johnson, B. D.; Lenhard, R. H.; Schaub, R. E.; Wissner, A. Imidazo[ 1,5-d][ 1,2,4]triazines as Potential Antiasthma Agents J. Med. Chem. 1985, 28, 1704-1716 (Pubitemid 16204842)
20. Liu, S.; Bolger, J. K.; Kirkland, L. O.; Premnath, P. N.; McInnes, C. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements ACS Chem. Biol. 2010, 5, 1169-1182
21. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 (Pubitemid 27046991)
22. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases J. Comb. Chem. 1999, 1, 55-68
23. Kontopidis, G.; Andrews, M. J.; McInnes, C.; Plater, A.; Innes, L.; Renachowski, S.; Cowan, A.; Fischer, P. M. Truncation and optimization of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design ChemMedChem 2009, 4, 1120-1128
24. Andrews, M. J.; McInnes, C.; Kontopidis, G.; Innes, L.; Cowan, A.; Plater, A.; Fischer, P. M. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes Org. Biomol. Chem. 2004, 2, 2735-2741